Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Net Margin (2018 - 2025)

Historic Net Margin for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to 29.31%.

  • Dna X's Net Margin fell 125900.0% to 29.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.57%, marking a year-over-year decrease of 347300.0%. This contributed to the annual value of 58.83% for FY2024, which is 591800.0% down from last year.
  • Per Dna X's latest filing, its Net Margin stood at 29.31% for Q3 2025, which was down 125900.0% from 66.8% recorded in Q2 2025.
  • Over the past 5 years, Dna X's Net Margin peaked at 2.74% during Q1 2025, and registered a low of 148.56% during Q4 2024.
  • For the 5-year period, Dna X's Net Margin averaged around 37.86%, with its median value being 29.31% (2025).
  • In the last 5 years, Dna X's Net Margin soared by 687900bps in 2022 and then plummeted by -1416500bps in 2024.
  • Dna X's Net Margin (Quarter) stood at 73.7% in 2021, then skyrocketed by 93bps to 4.91% in 2022, then crashed by -41bps to 6.91% in 2023, then plummeted by -2050bps to 148.56% in 2024, then skyrocketed by 80bps to 29.31% in 2025.
  • Its Net Margin stands at 29.31% for Q3 2025, versus 66.8% for Q2 2025 and 2.74% for Q1 2025.